Quarter
Charts

PHARMACYTE BIOTECH, INC. — Key Metrics

3 years of history · ending 2025-04-30 · SEC EDGAR

Income StatementCash FlowBalance SheetKey Metrics

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Working Capital Analysis

Valuation Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$4
Book Value Per Share
$7
Free Cash Flow Per Share
$-0
Cash Per Share
$2
Revenue Per Share
$0
OCF Per Share
$-0
Return on Equity
77.1%
Return on Assets
53.3%
Return on Invested Capital
-8.7%
Debt to Equity
—
Current Ratio
7.68
Quick Ratio
7.68
Asset Turnover
0.00
Days Sales Outstanding
—
Days Payables Outstanding
—
Days Inventory On Hand
—
Cash Conversion Cycle
—
R&D / Revenue
—
SBC / Revenue
—
Working Capital
$19M
Net Current Asset Value
$19M
Invested Capital
$52M
OCF / Net Income
-0.10
FCF / Net Income
-0.10
Accruals Ratio (Sloan)
61.0%
Net Debt
$-16M
Net Debt / EBITDA
3.55
Interest Coverage
—
Cash Coverage
—
Tangible Common Equity
$50M
TCE / Total Assets
91.3%
NOPAT
$-3M
Cash ROIC
-7.5%
WC / Revenue
—
Reinvestment Rate
—
Total Payout Ratio
8.3%
Asset Growth vs Revenue Growth
—
Book Value 5Y CAGR
59.1%
Stock Price (FY-end)
$1
Market Cap
$9M
P/E Ratio
0.30
P/B Ratio
0.18
P/TB Ratio
0.18
Enterprise Value
$-6M
FCF Yield
-32.8%
Shareholder Yield
22.7%
Buyback Yield
28.0%
R&D Yield
4.8%
Graham Number
$26
Shares Variation (YoY)
-23.5%
Beta (5Y)
0.44
Cost of Equity
6.7%
Cost of Debt (after tax)
—
52W High
$2
52W Low
$1
Trailing Return 1Y
-41.2%
Trailing Return 5Y
-96.9%
F-Score (Piotroski)
4.00
Z-Score (Altman)
-0.33

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

Stock Price on Earnings Dates

PHARMACYTE BIOTECH, INC. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2012FY2013FY2014FY2018
Federal Statutory Rate———21.00%
State & Local Income Taxes————
Foreign Rate Differential————
Other Adjustments————
Effective Tax Rate34.00%34.00%34.00%—

Cash vs Accrual

ItemFY2012FY2013FY2014FY2018
Income Tax Expense (Accrual)————
Income Taxes Paid (Cash)———$800